Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy.

Dvela-Levitt M, Kost-Alimova M, Emani M, Kohnert E, Thompson R, Sidhom EH, Rivadeneira A, Sahakian N, Roignot J, Papagregoriou G, Montesinos MS, Clark AR, McKinney D, Gutierrez J, Roth M, Ronco L, Elonga E, Carter TA, Gnirke A, Melanson M, Hartland K, Wieder N, Hsu JC, Deltas C, Hughey R, Bleyer AJ, Kmoch S, Živná M, Barešova V, Kota S, Schlondorff J, Heiman M, Alper SL, Wagner F, Weins A, Golub TR, Lander ES, Greka A.

Cell. 2019 Jul 25;178(3):521-535.e23. doi: 10.1016/j.cell.2019.07.002.

PMID:
31348885
2.

A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.

Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL.

Nat Commun. 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9.

3.

Discovering metabolic disease gene interactions by correlated effects on cellular morphology.

Jiao Y, Ahmed U, Sim MFM, Bejar A, Zhang X, Talukder MMU, Rice R, Flannick J, Podgornaia AI, Reilly DF, Engreitz JM, Kost-Alimova M, Hartland K, Mercader JM, Georges S, Wagh V, Tadin-Strapps M, Doench JG, Edwardson JM, Rochford JJ, Rosen ED, Majithia AR.

Mol Metab. 2019 Jun;24:108-119. doi: 10.1016/j.molmet.2019.03.001. Epub 2019 Mar 13.

4.

Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.

Price C, Gill S, Ho ZV, Davidson SM, Merkel E, McFarland JM, Leung L, Tang A, Kost-Alimova M, Tsherniak A, Jonas O, Vazquez F, Hahn WC.

Cancer Res. 2019 May 15;79(10):2564-2579. doi: 10.1158/0008-5472.CAN-18-2674. Epub 2019 Mar 21.

PMID:
30898838
5.

Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes.

Bray MA, Singh S, Han H, Davis CT, Borgeson B, Hartland C, Kost-Alimova M, Gustafsdottir SM, Gibson CC, Carpenter AE.

Nat Protoc. 2016 Sep;11(9):1757-74. doi: 10.1038/nprot.2016.105. Epub 2016 Aug 25.

6.

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.

Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, Lee Y, Goodale A, Cherniack AD, Oh C, Kryukov G, Cowley GS, Garraway LA, Stegmaier K, Roberts CW, Golub TR, Meyerson M, Root DE, Tsherniak A, Hahn WC.

Cancer Discov. 2016 Aug;6(8):914-29. doi: 10.1158/2159-8290.CD-16-0154. Epub 2016 Jun 3.

7.

Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery.

Zhan Y, Kost-Alimova M, Shi X, Leo E, Bardenhagen JP, Shepard HE, Appikonda S, Vangamudi B, Zhao S, Tieu TN, Jiang S, Heffernan TP, Marszalek JR, Toniatti C, Draetta G, Tyler J, Barton M, Jones P, Palmer WS, Geck Do MK, Andersen JN.

Epigenetics Chromatin. 2015 Sep 21;8:37. doi: 10.1186/s13072-015-0026-4. eCollection 2015.

8.

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, Heffernan TP, Marszalek JR, Toniatti C, Petrocchi A, Verhelle D, Owen DR, Draetta G, Jones P, Palmer WS, Sharma S, Andersen JN.

Cancer Res. 2015 Sep 15;75(18):3865-3878. doi: 10.1158/0008-5472.CAN-14-3798. Epub 2015 Jul 2.

9.

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.

Palmer WS, Poncet-Montange G, Liu G, Petrocchi A, Reyna N, Subramanian G, Theroff J, Yau A, Kost-Alimova M, Bardenhagen JP, Leo E, Shepard HE, Tieu TN, Shi X, Zhan Y, Zhao S, Barton MC, Draetta G, Toniatti C, Jones P, Geck Do M, Andersen JN.

J Med Chem. 2016 Feb 25;59(4):1440-54. doi: 10.1021/acs.jmedchem.5b00405. Epub 2015 Jul 6.

10.

Utilizing murine inducible telomerase alleles in the studies of tissue degeneration/regeneration and cancer.

Shingu T, Jaskelioff M, Yuan L, Ding Z, Protopopov A, Kost-Alimova M, Hu J.

J Vis Exp. 2015 Apr 13;(98). doi: 10.3791/52599.

11.

Telomere dysfunction suppresses multiple endocrine neoplasia in mice.

Lee JH, Anver M, Kost-Alimova M, Protopopov A, DePinho RA, Rane SG.

Genes Cancer. 2014 Sep;5(9-10):306-19.

12.

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF.

Nature. 2014 Oct 30;514(7524):628-32. doi: 10.1038/nature13611. Epub 2014 Aug 10.

13.

Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy.

Mourkioti F, Kustan J, Kraft P, Day JW, Zhao MM, Kost-Alimova M, Protopopov A, DePinho RA, Bernstein D, Meeker AK, Blau HM.

Nat Cell Biol. 2013 Aug;15(8):895-904. doi: 10.1038/ncb2790. Epub 2013 Jul 7.

14.

Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases.

Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR, Jiang S, Li L, Horner JW, Wang YA, Chin L, DePinho RA.

Cell. 2012 Mar 2;148(5):896-907. doi: 10.1016/j.cell.2012.01.039. Epub 2012 Feb 16.

15.

Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer.

Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, Ding Z, Ying H, Boutin AT, Zhang H, Johnson S, Ivanova E, Kost-Alimova M, Protopopov A, Wang YA, Shirihai OS, Chin L, DePinho RA.

Cell. 2012 Feb 17;148(4):651-63. doi: 10.1016/j.cell.2011.12.028.

16.

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.

Blood. 2011 Apr 28;117(17):4409-19. doi: 10.1182/blood-2010-02-267344. Epub 2011 Feb 14.

17.

Telomere dysfunction induces metabolic and mitochondrial compromise.

Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA.

Nature. 2011 Feb 17;470(7334):359-65. doi: 10.1038/nature09787. Epub 2011 Feb 9. Erratum in: Nature. 2011 Jul 14;475(7355):254.

18.

Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice.

Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, Sahin E, Kost-Alimova M, Protopopov A, Cadiñanos J, Horner JW, Maratos-Flier E, Depinho RA.

Nature. 2011 Jan 6;469(7328):102-6. doi: 10.1038/nature09603. Epub 2010 Nov 28.

19.

Horizontal transfer of tumor DNA to endothelial cells in vivo.

Ehnfors J, Kost-Alimova M, Persson NL, Bergsmedh A, Castro J, Levchenko-Tegnebratt T, Yang L, Panaretakis T, Holmgren L.

Cell Death Differ. 2009 May;16(5):749-57. doi: 10.1038/cdd.2009.7. Epub 2009 Feb 13.

20.

Microdissection molecular copy-number counting (microMCC)--unlocking cancer archives with digital PCR.

McCaughan F, Darai-Ramqvist E, Bankier AT, Konfortov BA, Foster N, George PJ, Rabbitts TH, Kost-Alimova M, Rabbitts PH, Dear PH.

J Pathol. 2008 Nov;216(3):307-16. doi: 10.1002/path.2413.

PMID:
18773450

Supplemental Content

Loading ...
Support Center